Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EP... (les are expected to remain in line with ...)

HOME >> BIOLOGY >> TECHNOLOGY

Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.

Date:10/23/2007

les are expected to remain in line with year-to-date

performance and achieve the Company's 7% organic growth goal. The

acquisition of Epichem is expected to add an additional 2% in growth

for the full year. Currency benefits could add more than 4% to these

growth estimates if currency exchange rates remain at September 30,

2007 levels.

-- Management is raising its 2007 diluted EPS forecast by $.05 to a new

range of $2.25 to $2.35 to reflect improved pretax margin

expectations, realized and expected currency benefits and a more

favorable full year tax rate than that used in previous forecasts.

CEO's STATEMENT:

Commenting on third quarter performance and expectations for the full year of 2007, President and CEO Jai Nagarkatti said: "We are very pleased that improved growth this quarter produced quarterly sales in excess of $500 million for the second successive quarter. The key initiatives supporting our customer centric sales focus enabled us to deliver organic sales growth at our targeted 7% level and add another 3% from acquisitions. And, we expect similar performance for the final quarter of 2007. We continued to add new programs to support this sales growth objective while maintaining profit levels. So I'm confident about our ability to deliver both our targeted sales growth and our increased EPS forecast of $2.25 to $2.35 when we report our 2007 results next February. Changes in our management team at the beginning of the quarter brought new energy to these efforts and have sharpened our focus even further. And our previously announced supply chain initiative is well under way. We remain confident about the rest of 2007, 2008 and beyond as we remain focused on achieving the strategic plan objectives we set two years ago."

Nagarkatti continued, "Third quarter achievements and expectations for our five key growth initiatives included:

-- Continuing to
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related biology technology :

1. Jellyfish partners for sales tracking technology
2. Doyle wants sales tax applied to digital downloads
3. Mortgagebot builds online sales even as housing declines
4. Third Wave reports another loss, stronger sales
5. Johnson Controls reports record quarterly sales
6. Can sales outsourcing grow Wisconsin biotechs?
7. Sonic Foundry reports quarterly loss, higher Mediasite sales
8. My-oh, its BIO! Where sales hype and science collide
9. Third Wave shuffles finance, sales management
10. Johnson Controls sales up, profits down
11. Turning ads into sales: Context is king

Post Your Comments:

Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EP...(les are expected to remain in line with ...)